Literature DB >> 19675532

Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder.

Sagnik Bhattacharyya1, Sumant Khanna, Koushik Chakrabarty, Anita Mahadevan, Rita Christopher, S K Shankar.   

Abstract

Although serum autoantibodies directed against basal ganglia (BG) implicate autoimmunity in the pathogenesis of obsessive-compulsive disorder (OCD), it is unclear whether these antibodies can cross the blood-brain barrier to bind against BG or other components of the OCD circuit. It is also unclear how they might lead to hyperactivity in the OCD circuit. We examined this by investigating the presence of autoantibodies directed against the BG or thalamus in the serum as well as CSF of 23 OCD patients compared with 23 matched psychiatrically normal controls using western blot. We further investigated CSF amino acid (glutamate, GABA, taurine, and glycine) levels and also examined the extent to which these levels were related to the presence of autoantibodies. There was evidence of significantly more binding of CSF autoantibodies to homogenate of BG as well as to homogenate of thalamus among OCD patients compared with controls. There was no significant difference in binding between patient and control sera except for a trend toward more bands to BG and thalamic protein corresponding to 43 kD among OCD patients compared with controls. CSF glutamate and glycine levels were also significantly higher in OCD patients compared with controls, and further multivariate analysis of variance showed that CSF glycine levels were higher in those OCD patients who had autoantibodies compared with those without. The results of our study implicate autoimmune mechanisms in the pathogenesis of OCD and also provide preliminary evidence that autoantibodies against BG and thalamus may cause OCD by modulating excitatory neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19675532     DOI: 10.1038/npp.2009.77

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  49 in total

Review 1.  Pharmacological treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Michael H Bloch
Journal:  Psychiatr Clin North Am       Date:  2014-07-24

2.  Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder.

Authors:  Sophia Attwells; Elaine Setiawan; Alan A Wilson; Pablo M Rusjan; Romina Mizrahi; Laura Miler; Cynthia Xu; Margaret Anne Richter; Alan Kahn; Stephen J Kish; Sylvain Houle; Lakshmi Ravindran; Jeffrey H Meyer
Journal:  JAMA Psychiatry       Date:  2017-08-01       Impact factor: 21.596

3.  Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial.

Authors:  Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi
Journal:  Neuropsychopharmacology       Date:  2017-04-04       Impact factor: 7.853

4.  Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders.

Authors:  Lior Brimberg; Itai Benhar; Adita Mascaro-Blanco; Kathy Alvarez; Dafna Lotan; Christine Winter; Julia Klein; Allon E Moses; Finn E Somnier; James F Leckman; Susan E Swedo; Madeleine W Cunningham; Daphna Joel
Journal:  Neuropsychopharmacology       Date:  2012-04-25       Impact factor: 7.853

5.  Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression.

Authors:  Claudia Delgado-Acevedo; Sebastián F Estay; Anna K Radke; Ayesha Sengupta; Angélica P Escobar; Francisca Henríquez-Belmar; Cristopher A Reyes; Valentina Haro-Acuña; Elías Utreras; Ramón Sotomayor-Zárate; Andrew Cho; Jens R Wendland; Ashok B Kulkarni; Andrew Holmes; Dennis L Murphy; Andrés E Chávez; Pablo R Moya
Journal:  Neuropsychopharmacology       Date:  2018-12-26       Impact factor: 7.853

Review 6.  Obsessive-Compulsive Disorder: Autoimmunity and Neuroinflammation.

Authors:  Mona Gerentes; Antoine Pelissolo; Krishnamoorthy Rajagopal; Ryad Tamouza; Nora Hamdani
Journal:  Curr Psychiatry Rep       Date:  2019-08-01       Impact factor: 5.285

7.  Immunoglobulin A Dysgammaglobulinemia Is Associated with Pediatric-Onset Obsessive-Compulsive Disorder.

Authors:  Kyle Williams; Leah Shorser-Gentile; Suraj Sarvode Mothi; Noah Berman; Mark Pasternack; Daniel Geller; Jolan Walter
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-03-20       Impact factor: 2.576

Review 8.  Autoimmunity, Autoantibodies, and Autism Spectrum Disorder.

Authors:  Elizabeth Edmiston; Paul Ashwood; Judy Van de Water
Journal:  Biol Psychiatry       Date:  2016-09-01       Impact factor: 13.382

Review 9.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

10.  In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

Authors:  Mohammad Haghighi; Leila Jahangard; Hamid Mohammad-Beigi; Hafez Bajoghli; Hassan Hafezian; Alireza Rahimi; Hamid Afshar; Edith Holsboer-Trachsler; Serge Brand
Journal:  Psychopharmacology (Berl)       Date:  2013-03-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.